Skip to main content

Misleading Advertising Lawsuit Over Baby Powder Dismissed

Misleading Advertising Lawsuit Over Baby Powder Dismissed

Misleading Advertising Lawsuit Over Baby Powder Dismissed

Introduction

On January 22, U.S. District Judge Todd W. Robinson of the Southern District of California favored Johnson & Johnson (J&J) Consumer Inc. and Bausch Health US LLC over a lawsuit that claimed the defendants for misleading representations in advertising and marketing of the talcum products.

The lawsuit was brought by two plaintiffs seeking damages on behalf of all purchasers of the talcum powder products in the state of California. The plaintiffs contended that the products contained contaminants like asbestos, lead, silica, and arsenic that can cause cellular inflammation and oxidative stress.

J&J and the co-defendant were alleged of engaging in deceptive advertising practices for its baby powder and other talc-based products as an effort to obtain consumers' trust and increase sales.

The defendants filed a motion to dismiss, arguing that the plaintiffs failed to show that the alleged misrepresentations are in fact misleading and they have not satisfied Rule 9(b). Under Rule 9(b), the plaintiff must state with “particularity the circumstances constituting the fraud or mistake.”

According to the recent order, Judge Robinson stated that the plaintiffs failed to identify which particular advertisement they relied on and that they failed to show which specific statement they actually saw. Additionally, the judge said that the plaintiffs failed to show the products are unsafe and dismissed the case with prejudice.

Earlier this month, the Baby Powder giant argued over the Plaintiffs’ Steering Committee's (PSC) motion to add a spoliation of evidence claim to the First Amended Master Long Form Complaint, stating that it's untimely for the plaintiffs to add the claim four years after the first Master Complaint was filed.

J&J is currently facing more than 20,000 Baby Powder and Shower-to-Shower lawsuits and has been paying millions to resolve them.

Last year the company stopped selling its talcum-based products in the U.S. and Canada, stating a decline in consumer demand and misinformation about the safety of the products.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!